Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis.

Citation metadata

Date: Apr. 15, 2022
Publisher: Hindawi Limited
Document Type: Article
Length: 6,117 words
Lexile Measure: 1280L

Document controls

Main content

Abstract :

This study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence interval (CI) were applied to assess outcomes. Eighteen randomized controlled trials involved 8,847 neovascular AMD patients were selected for the meta-analysis. Pegaptanib (WMD: 6.70; P

Source Citation

Source Citation   

Gale Document Number: GALE|A701486822